Numinus (NUMI)

Numinus Company information 

Numinus is a company taking a leading role in providing solutions to the prevalent global mental health crisis. 

The company was the first-ever publicly-traded company in Canada to receive a license from Health Canada, permitting it to conduct research revolving around psilocybin i.e its production and extraction process from magic mushrooms. 

Consequently, Numinus became the first company to conduct the process of harvesting psilocybin in October 2020 legally. 

The company incorporated three different pathways into their psychedelic-assisted psychotherapies: compassionate access trials, ketamine-assisted therapy, and special Access.  

Numinus’ Vision 

Despite the current broken state of the mental healthcare system, Numinus believes that the situation can be fixed.

The company envisions a world where everyone knows about and has Access to mental healing and wellness. 

Numinus aims to create solutions that bring a positive transition to the mental health landscape. This can be achieved through the creation and development of highly functional psychedelic-assisted psychotherapy.

Numinus biosciences lab

The Numinus Biosciences Lab’s mission is to provide unending support towards expanding evidence-backed, safe, and accessible PAP (psychedelic-assisted psychotherapy).

The state-of-the-art lab is located in BC, Canada. It has a license from Health Canada granting it a permit to possess, produce, sell, export, and deliver various natural source materials psychedelic compounds. This list includes ketamine, psilocybin, LSD, DMT, psilocin, and Mescaline. 

Through evidence-based treatment and analytical testing services, the biosciences lab ensures that they offer safe and reliable products to millions of individuals worldwide. 

Its main goal is to promote psychedelic-centered initiatives and help attain the industry’s objectives that promote health and wellbeing. 

Numinus clinics

The Numinus Clinics are created to help health practitioners learn the basics and the intricacies of psychedelic-assisted psychotherapy. By understanding PAP and what it entails, including the best practices, practitioners can help many patients achieve optimum wellness goals. 

The company offers its Numinus-owned training, facilities, and resources in this training. 

Initially, the brand started with the Vancouver clinic, but after acquiring Mindspace company, it expanded to three clinic locations.

Numinus clinics incorporate the following pathways into their psychedelic-assisted psychotherapies:

Ketamine-assisted psychotherapy

This type of psychotherapy is effective in dealing with treatment-resistant depression.

Special Access for psilocybin & MDMA

This pathway is designed for individuals with life-threatening conditions.

Compassionate access trials for psilocybin & MDMA

The Numinus’ medical team is planning to conduct two compassionate access clinical trials in their Vancouver clinic. Both trials target Canadian citizens. 

• Psilocybin-assisted psychotherapy, which looks into how psilocybin can be used to treat and manage substance use disorders.

MDMA-assisted psychotherapy, which will target PTSD. The company will conduct this study in collaboration with the Multidisciplinary Association for Psychedelics Studies (MAPS).